Objective: To examine cardiovascular disease (CVD) mortality risk in men with diabetes only, metabolic syndrome only, and concurrent metabolic syndrome and diabetes.

Research Design And Methods: We examined CVD mortality risk by metabolic syndrome and diabetes status in men from the Aerobics Center Longitudinal Study (ACLS) (mean +/- SD age 45.1 +/- 10.2 years). Participants were categorized as having neither diabetes nor metabolic syndrome (n = 23,770), metabolic syndrome only (n = 8,780), diabetes only (n = 532), or both (n = 1,097). The duration of follow-up was 14.6 +/- 7.0 years with a total of 483,079 person-years of exposure and 1,085 CVD deaths.

Results: Age-, examination year-, and smoking-adjusted CVD death rates (per 1,000 man-years) in men with neither metabolic syndrome nor diabetes, metabolic syndrome only, diabetes only, and both were 1.9, 3.3, 5.5, and 6.5, respectively. CVD mortality was higher in men with metabolic syndrome only (hazard ratio 1.8 [95% CI 1.5-2.0]), diabetes only (2.9 [2.1-4.0]), and both (3.4 [2.8-4.2]) compared with men with neither. The presence of metabolic syndrome was not associated (1.2 [0.8-1.7]) with higher CVD mortality risk in individuals with diabetes. In contrast, the presence of diabetes substantially increased (2.1 [1.7-2.6]) CVD mortality risk in individuals with metabolic syndrome.

Conclusions: The presence of diabetes was associated with a threefold higher CVD mortality risk, and metabolic syndrome status did not modify this risk. Our findings support the fact that physicians should be aggressive in using CVD risk-reducing therapies in all diabetic patients regardless of metabolic syndrome status.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699717PMC
http://dx.doi.org/10.2337/dc08-1871DOI Listing

Publication Analysis

Top Keywords

metabolic syndrome
48
cvd mortality
24
mortality risk
20
syndrome diabetes
16
metabolic
13
diabetes metabolic
12
diabetes
11
syndrome
11
cvd
9
cardiovascular disease
8

Similar Publications

[Surgical treatment for obesity - metabolic surgery].

Orthopadie (Heidelb)

January 2025

Klinikum Dortmund, Klinik für Chirurgie, Klinikum der Universität Witten/Herdecke, Beurhausstraße 40, 44137, Dortmund, Deutschland.

Background: Over the past 20 years, surgical treatment of obesity, or metabolic surgery, has established itself as an extremely efficient and sustainable therapy for treating severely overweight patients. Compared to non-surgical weight reduction procedures, surgical techniques have been shown to be superior in all studies, both in terms of short-term and long-term effectiveness. On the other hand, the invasiveness of the procedures is something that many patients view critically.

View Article and Find Full Text PDF

Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review.

Dermatol Ther (Heidelb)

January 2025

Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Introduction: Psoriasis is a systemic inflammatory disease with increased cardiometabolic risk including dyslipidaemia and diabetes. Biologic therapy effectively treats the cutaneous inflammatory burden of psoriasis and evolving evidence suggests potential to reduce systemic inflammatory sequalae that can elevate cardiovascular risk. This study aimed to assess the change in cardiometabolic risk markers in a cohort of patients with psoriasis treated with 1 year of continuous biologic treatment.

View Article and Find Full Text PDF

Previous studies have shown that serum albumin levels are associated with a greater risk of metabolic syndrome (MetS). However, it is unclear whether this association is causal or only influenced by confounding factors, so further investigation is needed to determine the causal relationships. Researchers selected participants with serum albumin, metabolic syndrome, and related covariates from the National Health and Nutrition Examination Survey (NHANES) database for a total of 14,036 individuals, including 5483 individuals with MetS and 8553 individuals without MetS.

View Article and Find Full Text PDF

Acetate ameliorates ovarian mitochondrial dysfunction in letrozole-induced polycystic ovarian syndrome rat model by improving mitofusin-2.

J Physiol Sci

January 2025

Cardio/Endo-metabolic and Microbiome Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, P.M.B. 5454, 360101, Ado-Ekiti, Nigeria.

Androgen excess and metabolic abnormality largely contribute to the pathogenesis of polycystic ovarian syndrome (PCOS), which primarily precipitates ovarian dysfunction and infertility in reproductive-age women. Impaired mitochondrial function and epigenetic alteration have been linked to the development of PCOS. However, it is unknown whether acetate would exert a therapeutic effect on ovarian mitochondrial dysfunction in PCOS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!